Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Monday November 23 2009 | Biotechnology feed | All feeds
|
|
|
BioInvent Issued US Patent for n-CoDeR Antibody Library 11th January 2006 Lund, Sweden:
Lund, Sweden:
BioInvent International AB (SAX:BINV), the antibody development
company listed on the O-list of the Stockholm Exchange, announced
today that the US Patent Office has granted a new patent covering
its n-CoDeRÒ
antibody library.
The antibody library n-CoDeRÒ is an essential part of BioInvent's technology platform and enables the fast and efficient discovery of human antibodies. It is utilised in the development of proprietary drug candidates in diseases areas as HIV, atherosclerosis, cancer and osteoarthritis as well as in development partnerships with pharmaceutical and biotech companies.
The
issued patent covers methods for preparation of the n-CoDeRÒ
antibody library as well as methods
for preparing the separate antibody components included in the
library. BioInvent has already obtained corresponding patents in
Europe, Japan and Australia. In August 2004, Maxygen, Inc. and
Novozymes A/S filed oppositions with the European Patent Office
against the European patent. These oppositions will be subject to a
hearing March 16. "The US Patent strengthen our efforts in building a competitive portfolio of drug candidates through increased patent protection around our product candidates" commented Svein Mathisen, President and CEO of BioInvent. To date, BioInvent has more than 160 individual patents and patent applications pending worldwide either licensed exclusively or filed in its name. The patents and pending applications cover the core technology to discover antibody candidates and various aspects thereof, as well as antibody product candidates in development and their use in therapy. The new patent has the number US 6 989 250 and is entitled “A method for in vitro molecular evolution of protein function” --THE END— For more information BioInvent International AB Svein Mathisen Cristina Glad President & CEO Executive Vice President Tel: +46 (0)46-286 85 67 Tel: +46 (0)46-286 85 51 Mobile: +46 (0)708-97 82 13 Mobile: +46 (0)708-16 85 70 E-mail: svein.mathisen@bioinvent.com E-mail: cristina.glad@bioinvent.com Northbank Communications Katja Stout/Christelle Kerouedan Phone: +44 (0)20 7886 8150 E-mail: c.kerouedan@northbankcommunications.com Legal disclaimer This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release. Notes to editors: BioInvent International AB, which is listed on the O list of the Stockholm Stock Exchange (SAX:BINV), develops therapeutic antibodies against diseases where there is a significant unmet medical need. Antibodies are a strongly growing segment of the pharmaceutical market. BioInvent focuses on discovery and development of therapeutic antibodies, and documents their effect in pre-clinical and early clinical trials. Clinical development, marketing and distribution are conducted in cooperation with established pharmaceutical companies. Today BioInvent conducts innovative drug projects involving conditions such as HIV infection, thrombosis, cancer, atherosclerosis and diseases of the joints. These projects are based on a competitive technology platform that covers the entire chain from the n-CoDeRÒ antibody library for fast and efficient selection of human antibodies, to production in a facility fully approved for manufacturing biological drugs. The scope and strength of this platform is also utilised by partners in the development of new drugs. These partners include ALK-Abelló, Antisoma, Celltech, GlaxoSmithKline, Igeneon, ImmunoGen, OrbusNeich, Syngenta and XOMA. The Company, which currently has 92 employees, is located at Ideon in Lund. BioInvent International AB (publ) Co. reg. no. 556537-7263, Address: Sölvegatan 41 Mailing address: 223 70 LUND Tel: +46 (0)46 286 85 50
|
|
|
